Collage Venture Partners

Retension Pharmaceuticals is a healthcare company.Heart disease remains the leading cause of death worldwide. Nearly 50% of adult Americans have elevated blood pressure.

Response Pharmaceuticals is a biotechnology company developing treatments for cardiometabolic risk factors associated with antipsychotic drugs. Its primary focus is on managing post-prandial triglyceride levels, body weight, and other related health issues in patients discontinuing semaglutide or tirzepatide.

Bond Biosciences, Inc. is a biopharmaceutical company established in 2015 and headquartered in New York. The company specializes in the development of innovative, non-absorbed oral therapeutics aimed at addressing iron overload disorders and other ion-related diseases. By creating small molecule-based chelators that bind excess ions locally in the gastrointestinal tract, Bond Biosciences seeks to offer effective treatment options that allow patients to manage their conditions more simply and effectively. The focus on non-systemic therapies positions the company to provide solutions that minimize systemic side effects while targeting specific health issues related to metal overload.

Bond Biosciences, Inc. is a biopharmaceutical company established in 2015 and headquartered in New York. The company specializes in the development of innovative, non-absorbed oral therapeutics aimed at addressing iron overload disorders and other ion-related diseases. By creating small molecule-based chelators that bind excess ions locally in the gastrointestinal tract, Bond Biosciences seeks to offer effective treatment options that allow patients to manage their conditions more simply and effectively. The focus on non-systemic therapies positions the company to provide solutions that minimize systemic side effects while targeting specific health issues related to metal overload.